Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
MEDI3185 is a monoclonal antibody biosimilar designed to inhibit the stromal cell-derived factor 1 (SDF-1) receptor commonly referred to as CXCR4. This biosimilar targets CXCR4 to disrupt its interaction with the ligand SDF-1 which plays a crucial role in various physiological processes including hematopoiesis angiogenesis and immune surveillance. In pathological scenarios such as cancer high CXCR4 expression is associated with tumor progression metastasis and poor prognosis making MEDI3185 a significant asset in experimental cancer therapy research. Its mechanism involves steric hindrance with CXCR4's ligand-binding domain which is crucial for inhibiting the receptor's pro-metastatic signaling pathways. MEDI3185's IgG1 isotype is produced in XtenCHO cells and is formulated in a phosphate-buffered saline solution for research purposes providing stability and efficacy in laboratory settings focused on understanding and intervening in CXCR4-related pathways.
仅用于科研。不用于诊断过程。未经明确授权不得转售。